The upcoming American Society of Clinical Oncology (ASCO) Annual Meeting will be a pivotal stage for AbbVie Inc., as they showcase key data from their expansive oncology portfolio. A significant highlight of the event will be the presentation of results from the Phase 1b/2 CADENZA trial of PVEK monotherapy for blastic plasmacytoid dendritic cell neoplasm […]
Tag: AbbVie
AbbVie’s Allergan Trims Staff Post Failed Marketing Campaign
In a classic example of the adage, “if it ain’t broke, don’t fix it,” AbbVie’s Allergan, a vanguard in the aesthetics industry, is grappling with the fallout from a marketing strategy that failed to strike a chord with its service providers. Following a less than stellar performance of its revamped Allē loyalty program, Allergan has […]
FDA Accelerates Approval for AbbVie’s Emrelis in NSCLC
In a pivotal advancement for personalized medicine, the FDA has recently granted accelerated approval to AbbVie’s Emrelis, a targeted therapy for non-squamous non-small cell lung cancer (NSCLC) patients with high c-Met protein overexpression. This breakthrough signifies a critical leap forward in the pursuit of precision oncology, providing a much-needed treatment alternative for a specific subset […]
Addressing High Drug Costs Through Patent Reform
High drug prices have become a significant issue in the United States, a symptom of a patent system that often serves entrenched interests rather than promoting innovation and improving social welfare. The problem is particularly acute in the pharmaceutical sector, where patent strategies, like those employed by AbbVie with Humira, hinder competition and maintain market […]
Revolutionizing Cancer Therapy: ASCO 2025 Highlights
Antibody Drug Conjugates (ADCs) have been a game-changer in precision oncology over the past 25 years. Originally a bold concept, ADCs have now become a cornerstone in treating both blood cancers and solid tumors. The latest generation of ADCs features advanced technologies like smarter linkers, novel payloads, and higher drug-antibody ratios, pushing the boundaries of […]
Growing Pharma Tuck-In Deals Post-Mediocre Small Biotech Q1
Following a lackluster first quarter for small biotechs, the pharmaceutical industry is witnessing a surge in tuck-in deals. Ventyx, with upcoming Phase II Parkinson’s disease results, struck a deal with Sanofi granting the pharma right of first negotiation (ROFN) on an acquisition. This agreement, driven by a shared interest in novel central nervous system therapies, […]
